Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141984 | 0.84 | DGAT1 (0.41) | DGAT1ALDH1A1TSHR | |
| SCHEMBL28873923 | 0.78 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL617762 | 0.77 | DGAT1 (0.43) | DGAT1ALDH1A1TSHR | |
| SCHEMBL18614220 | 0.76 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL18614279 | 0.76 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1486198 | 0.75 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL28535462 | 0.75 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL27721975 | 0.75 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL27482953 | 0.75 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR | |
| SCHEMBL27859821 | 0.75 | DGAT1 (0.44) | DGAT1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608822-A1 | NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-120077036-A | Novel substituted pioglitazone oxazine carboxamide derivatives | 勃林格殷格翰国际有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024089227-A1 | NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-02 | — | — | WO | disclosed |
| CN-117186134-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111712302-B | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022178215-A1 | AMINO AMIDE TETRAHYDRO IMIDAZO PYRIDINES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-111712302-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-104211689-B | Antiviral compounds | 吉利德制药有限责任公司 | 2017-01-18 | — | — | CN | disclosed |
| CN-1974596-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2010-07-28 | — | — | CN | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-101024671-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-08-29 | — | — | CN | disclosed |
| CN-1974596-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-06-06 | — | — | CN | disclosed |
| CN-1299677-C | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-02-14 | — | — | CN | disclosed |
| CN-1668297-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | DGAT1 2583/4885ALDH1A1 764/4885TSHR 4619/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | DGAT1 2583/4885ALDH1A1 764/4885TSHR 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.